Cat. No. 3780
Chemical Name: 2-[[[4-(4-Fluorophenoxy)phenyl]sulfonyl]amino]-N-hydroxy-2-methylpropanamide
Biological ActivityBroad spectrum MMP inhibitor (IC50 values are 0.7, 0.9, 13, 16 and 1170 nM for MMP-2, MMP-13, MMP-9, MMP-3 and MMP-1 respectively). Attenuates early left ventricular dilation after experimental myocardial infarction in mice.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Rohde et al (1999) Matrix metalloproteinease inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99 3063. PMID: 10368126.
Lindsey et al (2002) Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105 753. PMID: 11839633.
Fang et al (2007) Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J.Mol.Cell.Cardiol. 43 535. PMID: 17689559.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: CP 471474, supplier, CP471474, MMP, matrix, metalloproteinase, metalloprotease, inhibitors, broad, spectrum, proteinases, proteases, Pfizer
Find multiple products by catalog number
New Products in this Area
γ-secretease inhibitor; inhibits Notch pathwayCA 074
Selective cathepsin B inhibitorP005091
Meet your representative
October 15, 2013